|
A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects with a Urea Cycle Disorder with Inadequate Control on Standard of Care
|
Completed
|
KB195
|
2
|
K020-218
|
KKUH
|
|
A Phase 1/2 Open-label Clinical Study of hLB-001 Gene Therapy in Pediatric Patients With Methylmalonic Acidemia Characterized by MMUT Mutations
|
Ongoing
|
AAV-hHA-hMUT
|
1
|
LB001-001
|
King Abdulaziz Medical City NG (Riyadh)
|
|
A PARTIALLY DOUBLE-BLINDED, RANDOMIZED, CONTROLLED, PLACEBO-CONTROLLED STUDY, A PHASE III TRIAL OF SAFETY AND EFFICACY OF PREMEDICATION WITH DEXMEDETOMIDINE AND MIDAZOLAM IN PEDIATRIC PATIENTS
|
Ongoing
|
DEXMEDETOMIDINE
|
3
|
RAC# 21901310
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
"A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients with Sickle Cell Disease and Other Hemoglobinopathies "
|
Ongoing
|
HYDROXYUREA (HYDROXYCARBAMIDE)
|
3
|
CT20/008/R
|
King Abdulaziz Medical City NG (Riyadh)
|
|
A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19
|
Ongoing
|
Convalescent Plasma
|
2
|
20-COVID-19-01M
|
KFSH-D
|
|
A multinational, open-label, randomised, controlled trial to investigate efficacy and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors.
|
Ongoing
|
Mim8
|
3
|
NN7769-4514
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
"A Multinational, Open Label, Randomized, Active-controlled, 3-arm Parallel Group, 24-week Study Comparing the Combination of Glimepiride and Metformin Versus Glimepiride and Metformin Alone in Patients With Type 2 Diabetes "
|
Terminated
|
GLIMEPIRIDE-HOE490
|
3
|
GLIME_R_05809
|
KFSH
|
|
A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (NAVIGATOR)
|
Completed
|
Tezepelumab
|
3
|
D5180C00007
|
KAUH-J
|
|
A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (DESTINATION)
|
Ongoing
|
Tezepelumab
|
3
|
D5180C00018
|
KAUH-J
|
|
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
|
Rejected
|
Alogliptin
|
3
|
SYR-322_402
|
PSMMC
|
